A recent study demonstrated that gene therapy using a clinically applicable lentiviral vector could rescue the impaired anemia in both mouse and human RPS19-deficient DBA models, with a low risk of mutagenesis and a highly polyclonal insertion site pattern, providing evidence for a potential curable treatment for patients with RPS19-deficiency [5]. Here, RPS19 is linked to anemia (phenotype).